Chelation may help some heart patients: study

[Celebration]

7. I can also selectively quote

And regardless of the fact that the study results are still open to interpretation, Yancy applauds the NHLBI for studying chelation in a rigorous, scientific way. “We are intrigued the NHLBI has taken the initiative to support research in these provacative and controversial areas,” says Yancy. “If we are to be an evidence-based healthcare system, then we should seek evidence for all the different therapies being utilized, particularly those for which there are major unanswered questions, and chelation therapy was one of those.” Only by studying such controversial therapies can they be either validated or discredited and thus help patients to receive the latest and highest quality care.
Read more: http://healthland.time.com/2012/11/05/chelation-for-heart-disease-study-shows-promise-but-experts-are-divided/#ixzz2BaHYTIZS

Makes sense the it works in diabetes_AGE inhibitors work due to chelation--there is a mechamism.

http://diabetes.diabetesjournals.org/content/61/3/549

Chelation: A Fundamental Mechanism of Action of AGE Inhibitors, AGE Breakers, and Other Inhibitors of Diabetes Complications

Ryoji Nagai1,
David B. Murray2,
Thomas O. Metz3 and
John W. Baynes4⇓

+ Author Affiliations

1Department of Food and Nutrition, Japan Women’s University, Tokyo, Japan


2Department of Pharmacology, University of Mississippi, Oxford, Mississippi


3Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington


4Department of Pharmacology, Physiology and Neuroscience, University of South Carolina School of Medicine, Columbia, South Carolina.

Corresponding author: John W. Baynes, [e-mail].

R.N. and D.B.M. contributed equally to this work.


Abstract


This article outlines evidence that advanced glycation end product (AGE) inhibitors and breakers act primarily as chelators, inhibiting metal-catalyzed oxidation reactions that catalyze AGE formation. We then present evidence that chelation is the most likely mechanism by which ACE inhibitors, angiotensin receptor blockers, and aldose reductase inhibitors inhibit AGE formation in diabetes. Finally, we note several recent studies demonstrating therapeutic benefits of chelators for diabetic cardiovascular and renal disease. We conclude that chronic, low-dose chelation therapy deserves serious consideration as a clinical tool for prevention and treatment of diabetes complications.
Received August 11, 2011.
Accepted December 7, 2011.
© 2012 by the American Diabetes Association.